Panelists discuss how to balance achieving deeper MRD-negative responses against increased toxicity risks in transplant-ineligible patients by personalizing therapy through dose modifications, weekly ...

Of these progression-free patients, 12 from a single center with serial minimal residual disease (MRD) assessments were all MRD-negative and imaging-negative at year 5 or later after cilta-cel ...